Common Contracts
6 similar null contracts by Actinium Pharmaceuticals, Inc., Aeglea BioTherapeutics, Inc., Geron Corp, Quicklogic Corporation
Geron Corporation (a Delaware corporation) 41,999,998 shares of Common Stock Pre-Funded Warrants to Purchase up to 8,002,668 shares of Common Stock Underwriting AgreementGeron Corp • March 20th, 2024 • Pharmaceutical preparations • New York
Execution Version Actinium Pharmaceuticals, Inc. Common Stock, par value $0.001 per share, and Warrants to Purchase Common Stock Underwriting Agreement April 18, 2019 William Blair & Company, L.L.C. As representative of the several Underwriters named...New York • May 5th, 2020
Actinium Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”), for whom William Blair & Company, L.L.C. is acting as representative (the “Representative” or “you”), an aggregate of (i) 42,860,000 shares (the “Shares”) of common stock, par value $0.001 per share (the “Common Stock”) of the Company and (ii) warrants to purchase up to 42,860,000 shares of Common Stock in the form set forth on Exhibit A (the “Warrants” and, together with the Shares, the “Securities”). Each Share is being sold together with a Warrant to purchase one share of Common Stock at an exercise price of $0.50 per whole share of Common Stock. The shares of Common Stock underlying the Warrants are herein called the “Warrant Shares”).
EX-1.1 2 d567975dex11.htm EX-1.1 QUICKLOGIC CORPORATION 13,513,510 Shares of Common Stock, par value $0.001 per share, and Warrants to Purchase 5,405,404 Shares of Common Stock UNDERWRITING AGREEMENT May 24, 2018 CRAIG-HALLUM CAPITAL GROUP LLC As...New York • May 5th, 2020
QuickLogic Corporation, a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to sell to the several underwriters named in Schedule I hereto (the “Underwriters,” or each an “Underwriter”) (i) an aggregate of 13,513,510 shares (the “Shares”) of common stock, par value $0.001 per share (the “Common Stock”), of the Company, and (ii) warrants of the Company, in the form set forth in Exhibit A hereto, to purchase an aggregate of 5,405,404 shares of Common Stock (the “Warrant Shares”) at an exercise price of $1.38 per share (the “Warrants”). Each Share is being sold together with a Warrant to purchase four-tenths of a share of Common Stock. The Shares and the Warrant Shares consist of authorized but unissued shares of Common Stock to be issued and sold by the Company. The Shares, the Warrants and the Warrant Shares purchased pursuant to this Underwriting Agreement (this “Agreement”) are herein collectively called the “Securities.”
AEGLEA BIOTHERAPEUTICS, INC. 11,652,830 Shares of Common Stock, par value $0.0001 Pre-Funded Warrants to Purchase 13,610,328 Shares of Common Stock Underwriting AgreementAeglea BioTherapeutics, Inc. • April 28th, 2020 • Pharmaceutical preparations • New York
Aeglea BioTherapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of 11,652,830 shares (the “Underwritten Shares”) of Common Stock, par value $0.0001 per share, of the Company (the “Common Stock”), pre-funded warrants to purchase an aggregate of 13,610,328 shares of Common Stock in the form attached hereto as Exhibit A (the “Warrants”) and, at the option of the Underwriters, up to an additional 3,789,473 shares of Common Stock (the “Option Shares”). The Underwritten Shares and the Warrants are herein referred to as the “Underwritten Securities.” The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The Shares and Warrants are herein referred to as the “Securities.” The shares of Common Stock issuable upon exercise of the Warrants are herein referred to as the “Warrant
Actinium Pharmaceuticals, Inc. Common Stock, par value $0.001 per share, and Pre-Funded Warrants to Purchase Common Stock Underwriting AgreementActinium Pharmaceuticals, Inc. • April 24th, 2020 • Pharmaceutical preparations • New York
Actinium Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”), for whom H.C. Wainwright & Co., LLC is acting as representative (the “Representative” or “you”), (A) an aggregate of (i) 100,833,333 shares (the “Firm Shares”) of common stock, par value $0.001 per share (the “Common Stock”) of the Company and (ii) pre-funded warrants to purchase up to 82,500,001 shares of Common Stock in the form set forth on Exhibit A (the “Warrants” and, together with the Firm Shares, the “Firm Securities”), and (B) subject to the option described in Sections 2 and 4 hereof granted by the Company to the Underwriters, all or any part of 27,500,000 additional shares of Common Stock to cover over-allotments, if any (the “Option Shares” and, together with the Firm Shares, the “Shares”). The shares of Common Stock underlying the Warrants are herein called
QUICKLOGIC CORPORATION 13,513,510 Shares of Common Stock, par value $0.001 per share, and Warrants to Purchase 5,405,404 Shares of Common Stock UNDERWRITING AGREEMENTQuicklogic Corporation • May 29th, 2018 • Semiconductors & related devices • New York
QuickLogic Corporation, a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to sell to the several underwriters named in Schedule I hereto (the “Underwriters,” or each an “Underwriter”) (i) an aggregate of 13,513,510 shares (the “Shares”) of common stock, par value $0.001 per share (the “Common Stock”), of the Company, and (ii) warrants of the Company, in the form set forth in Exhibit A hereto, to purchase an aggregate of 5,405,404 shares of Common Stock (the “Warrant Shares”) at an exercise price of $1.38 per share (the “Warrants”). Each Share is being sold together with a Warrant to purchase four-tenths of a share of Common Stock. The Shares and the Warrant Shares consist of authorized but unissued shares of Common Stock to be issued and sold by the Company. The Shares, the Warrants and the Warrant Shares purchased pursuant to this Underwriting Agreement (this “Agreement”) are herein collectively called the “Securities.”
